Correlation Between Aerovate Therapeutics and Akari Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and Akari Therapeutics PLC, you can compare the effects of market volatilities on Aerovate Therapeutics and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Akari Therapeutics.

Diversification Opportunities for Aerovate Therapeutics and Akari Therapeutics

-0.81
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Aerovate and Akari is -0.81. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Akari Therapeutics go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Akari Therapeutics

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.5 times more return on investment than Akari Therapeutics. However, Aerovate Therapeutics is 1.98 times less risky than Akari Therapeutics. It trades about 0.17 of its potential returns per unit of risk. Akari Therapeutics PLC is currently generating about -0.21 per unit of risk. If you would invest  186.00  in Aerovate Therapeutics on September 1, 2024 and sell it today you would earn a total of  77.00  from holding Aerovate Therapeutics or generate 41.4% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Aerovate Therapeutics  vs.  Akari Therapeutics PLC

 Performance 
       Timeline  
Aerovate Therapeutics 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Akari Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Aerovate Therapeutics and Akari Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aerovate Therapeutics and Akari Therapeutics

The main advantage of trading using opposite Aerovate Therapeutics and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.
The idea behind Aerovate Therapeutics and Akari Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets